BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM
BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM cost control mechanism and are "not likely to continue" if pharmaceutical benefit management companies "become the dominant payer in the prescription market," according to a report by PRIME Institute Director Stephen Schondelmeyer, PhD. The report, entitled "Competition and Pricing Issues in the Pharmaceutical Market," was released at an Aug, 4 press conference sponsored by NARD and the National Association of Chain Drug Stores.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth